SCHEMBL29427113

SCHEMBL29427113

Cc1ccc(OC2CCC3(CNC3C(C)(C)C)C2)cc1C1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25412878 0.76 HTR2C (0.31) —
SCHEMBL29497425 0.76 HTR2C (0.31) —
SCHEMBL29426997 0.68 ABHD6 (0.48) —
SCHEMBL25412552 0.68 ABHD6 (0.48) —
SCHEMBL25434991 0.67 ABHD6 (0.44) —
SCHEMBL26785754 0.66 ABL1 (0.37) —
SCHEMBL26739269 0.63 MGLL (0.42) —
SCHEMBL29426759 0.63 MGLL (0.42) —
SCHEMBL14142880 0.63 GRM7 (0.44) —
SCHEMBL29497356 0.62 ABHD6 (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4217062-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 — — EP disclosed
WO-2022063784-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-31 — — WO disclosed
Send feedback